Issue of Equity in lieu of Non-Exec Director Fees

Aptamer

18/07/2025 07:00

RNS Number : 5713R

Aptamer Group PLC

18 July 2025

 

 

18 July 2025

 

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

Issue of Equity in lieu of Non-Executive Director Fees

 

Aptamer Group plc (AIM: APTA), the leading developer of next-generation synthetic binders delivering innovation to the life sciences industry, today announces that it has issued 2,968,695 new ordinary shares of 0.1 pence each ("Ordinary Shares") at an average issue price of 0.3368 pence per Ordinary Share to settle Non-Executive Director fees.

 

Director Fee Shares

 

Tim Sykes has agreed to take shares in lieu of his Non-Executive Director fees, to be issued to him on a quarterly basis. Today's share issue will cover the period 1 April 2025 to 30 June 2025, and the price of the share issue is based on the volume weighted average daily closing share price for the relevant quarter.

 

Following this transaction, Tim Sykes' total beneficial interest in the Company is 11,639,758 Ordinary Shares, representing approximately 0.49% of the Company's issued share capital.

 

Total Voting Rights

 

An application will be made for the admission of these shares to trading on AIM, which is expected to become effective on or around 24 July 2025.

 

Immediately following Admission, the Company will have 2,394,731,620 ordinary shares of £0.001 each in issue.  The Company does not hold any shares in treasury, and all of the Ordinary Shares have equal voting rights. Therefore, the figures above represent the total voting rights in the Company and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in the Company under the Rules.

 

Additional Information

 

The following disclosures are made in accordance with the requirements of the UK Market Abuse Regulation and provide detail in relation to the purchase of ordinary shares by directors and other PDMRs in the Company.

 

NOTIFICATIONS AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Tim Sykes
2
Reason for the notification
a)
Position/status
Non-Executive Director
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Aptamer Group plc
b)
LEI
213800Y4XGH3WJNBE686
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Ordinary shares of £0.001 each
Identification code
GB00BNRRP542
b)
Nature of the transaction
Award of shares
c)
Price(s) and volume(s)
Price(s)
Volume(s)
0.3368p
2,968,695
d)
Aggregated information
- Aggregated volume
2,968,695
- Price
0.3368p each
e)
Date of the transaction
18 July 2025
f)
Place of the transaction
Off market

 

- Ends -

 

For further information, please contact:

 

Aptamer Group plc
Arron Tolley,Chief Executive Officer
+44 (0) 1904 217 404
SPARK Advisory Partners Limited - Nominated Adviser
Andrew Emmott / Jade Bayat
+44 (0) 20 3368 3550
Turner Pope Investments (TPI) Limited - Broker
James Pope / Andrew Thacker
+44 (0) 20 3657 0050
Northstar Communications Limited - Investor Relations
Sarah Hollins
+44 (0) 113 730 3896

 

This announcement contains inside information for the purposes of the UK Market Abuse Regulation.

 

About Aptamer Group plc 

Aptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies.

Aptamer operates a fee-for-service business in the $210 billion market for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer® assets with partners, aiming for future licensing revenue.

Founded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.

To register for news alerts by email go to https://aptamergroup.com/investors/investor-news-email-alerts/

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
DSHBRGDRISBDGUR